Saxenda is approved for: Adults Adults with obesity (BMI of 30 kg/m or greater) Adults who are overweight (BMI of 27 kg/m or greater) and have at least one weight-related health condition, such as high blood pressure, type 2 diabetes, or high cholesterol Children aged 12 and older Adolescents with obesity who weigh more than 60 kg (132 pounds) Limitations of use Saxenda should not be used together with other medicines that contain liraglutide, such as Victoza, or with any other GLP-1 receptor agonist, such as Ozempic, Wegovy, or Trulicity The safety and effectiveness of Saxenda in children aged 12 to 17 years who have type 2 diabetes have not been established
Your doctor may want to see readings taken at different times of day, as both medications can affect blood pressure variably throughout the day depending on when they are administered and when they reach peak effect
For example, combinations of GLP-1/glucagon RA achieve more liver fat content reduction in people with MASLD compared to GLP-1 RA alone despite similar WL, likely due to the direct effect of glucagon on hepatic lipid oxidation [79]
Safety Position : Neither Eli Lilly nor independent investigators have endorsed higher doses
Another GLP-1 analogue, lixisenatide, was reported to prevent the acuteness of cardiovascular events in apolipoprotein E / insulin receptor substrate 2 +/ (APOE / irs2 +/ ) mice by reducing the size of AS plaques, increasing plaque stability, and promoting the conversion of macrophages to the anti-inflammatory M2 phenotype (129)